Biopharma company Cingulate announced a joint commercialization agreement with Indegene this week, which pushes forward Cingulate’s lead drug candidate for attention deficit/hyperactivity disorder ...
Cingulate Inc. shares surged 30.7% amid strong investor interest in its ADHD treatment technology. Trading volume was high, with 3.297 million shares traded, reflecting growing market attention. Don’t ...
KANSAS CITY, Kan. and PRINCETON, N.J., March 13, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug ...
Hosted on MSN
Cingulate Stock Snaps 2-Day Losing Streak As Roth Hikes Target On ADHD Drug Review; Retail Bets On Buyout Potential
Retail chatter around Cingulate picked up on Tuesday after Roth Capital Partners raised its price target to $17 from $10 and reaffirmed a ‘Buy’ rating. Cingulate Inc.’s stock snapped a two-day losing ...
KANSAS CITY, Kan., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform ...
Cingulate Inc. has been granted a European patent for its ADHD treatment, CTx-1301. Following the patent news, Cingulate's stock has surged by 302.9%, reflecting strong market confidence in the ...
KANSAS CITY, Kan., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company advancing next-generation treatments for ADHD and other CNS disorders, today announced ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Cingulate will use the money ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results